



Examining Brain Networks in Prescription Opioid Users

Suchismita Ray Ph.D*

Center of Alcohol Studies, Rutgers, The State University of New Jersey, NJ, USA

*Corresponding author: Suchismita Ray Ph.D, Center of Alcohol Studies, Rutgers, The State University of New Jersey, 607 Allison Road, Piscataway, NJ 08854, USA, Tel: (848) 445-9391; Fax: (732) 445-3500; E-mail: shmita@rutgers.edu

Received date: Mar 30, 2017; Accepted date: Mar 31, 2017; Published date: Apr 08, 2017

Copyright: © 2017 Ray S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Introduction

Prescription opioid dependence has reached epidemic proportions in the U.S. and internationally [1]. Overdose deaths involving prescription opioids have increased significantly since 1999; indeed from 1999 to 2015, more than 183,000 people have died in the U.S. from overdoses related to prescription opioids [2,3]. It is well known that drug addiction is a disease of the brain [4] and thus, there is a critical need to get a fundamental understanding of the effects of chronic prescription opioid use on the human brain specifically on brain function and structure.

Research has identified brain regions specifically associated with psychological processes underlying craving and substance use. A few studies have investigated cue reactivity [5-7], and attentional bias [8,9] to prescription opioid related picture cues in chronic users. Cue reactivity is defined as an observable, classically conditioned response to alcohol and drugs [10] that correlate modestly with self-reported craving [11], and attention bias refers to giving drug related cues an increased priority in cognitive processing [12]. Bunce et al. compared recently withdrawn Prescription Opioid Dependent (POD) patients with the patients in supervised residential care for 2-3 months using a prescription drug cue reactivity task. They monitored the prefrontal cortex with functional near-infrared spectroscopy during the cue reactivity task. The recently withdrawn patients showed increased activation to pill stimuli in the right dorsolateral prefrontal cortex relative to extended care patients. Also, POD chronic pain patients evidenced a significant attentional bias towards prescription opioid related cues whereas non-dependent users did not show any significant attention bias [8]. These studies suggest that prescription opioid cues in the environment acquire salience, initiate arousal, and bias attention, as do other types of drug related cues.

Yet, critical to our understanding of the neurobiology of chronic prescription opioid use is defining brain connectivity, that is, how the brain regions interact as opposed to focusing on the functionality of individual regions of interest in isolation. There are only two brain connectivity studies that have examined functional connectivity in the brain of the POD patients [8,13]. Resting State Functional Connectivity (RSFC), measured by the correlation of spontaneous fluctuations of Blood Oxygen Level-Dependent (BOLD) signals in different regions of the resting brain, is believed to provide a measure of the brain's functional organization [14,15]. Individuals with more intense chronic pain showed decreased RSFC between the perigenual anterior cingulate and the default mode (cognitive control) network likely reflecting reduced ability to govern pain-related thought processes [8]. Bilateral structural volumetric loss in the amygdala, significantly decreased anisotropy in axonal pathways specific to the amygdala, and significantly decreased RSFC for seed regions that included the anterior insula, nucleus accumbens and amygdala

subdivisions have been demonstrated in POD persons compared to healthy controls [13].

However, the effects of long term prescription opioid use on the large scale brain networks that have implications in drug addiction have not been examined. These large scale brain networks include default mode network [16]; salience network [17]; lateral visual network [17]; dorsal attention network [18]; and the Drug Cue Processing Network (DCPN) which is a part of the mesocorticolimbic and nigrostriatal system implicated in drug seeking behavior and continuation of drug use [19,20]. The DCPN captures elements of the default, salience, and executive control networks. Drug addiction causes changes in specific regions in the mesocorticolimbic and nigrostriatal system and these changes are manifested through clinical features of compulsive drug seeking, relapses despite negative consequences of using a drug, inhibitory control deficit and reward disturbances [19]. One drug cue reactivity study [6] has examined isolated brain area activation in response to prescription drug cues, but no study has examined structural and functional connectivity among brain areas within the DCPN and other large scale brain networks in prescription opioid users. It is essential to conduct such a study as the results will be the key to our understanding about brain networks reorganization due to prescription opioid addiction.

Directions for Future Research

The literature cited above suggests the following directions for future neurocognitive research on prescription opioid addiction. First, studies would do well to include a multimodal assessment of structural and functional brain changes in prescription opioid users' brain networks including DCPN. This would be achieved by using functional MRI and structural Diffusion Tensor Imaging (DTI) techniques and structural, functional and effective connectivity (which reveals a causal influence of one brain area on another) analysis to understand changes in brain networks due to long term prescription opioid use. It would also be important for future researchers to collect for the first time the structural, functional and effective connectivity data between the regions within different brain networks in PODs and matched controls. Data collection should be geared toward developing both pharmacologic and behavioral therapies in the treatment of relapse prevention in individuals with prescription opioid use disorder. Finally, translational constructs linking research to clinical applications should be explicated. Specifically, how therapies can be developed from brain connectivity research to change the neuroplasticity within the DCPN and other large brain networks. Restoring normal functioning of these networks holds promise in promoting abstinence from drug use in this high-risk population.

Acknowledgements

Research supported by a National Institute on Drug Abuse grant (K01 DA029047).

References

- 1. Dhalla IA, Persaud N, Juurlink DN (2011) Facing up to the prescription opioid crisis. BMJ 343: d5142.
- Back SE, Payne RL, Wahlquist AH, Carter RE, Stroud Z, et al. (2011) Comparative profiles of men and women with opioid dependence: Results from a national multisite effectiveness trial. Am J Drug Alcohol Abuse 37: 313-323.
- Back SE, Gros DF, McCauley JL, Flanagan JC, Cox E, et al. (2014) Laboratory-induced cue reactivity among individuals with prescription opioid dependence. Addict Behav 39: 1217-1223.
- Morphett K, Carter A, Hall W, Gartner C (2017) Framing tobacco dependence as a "brain disease": Implications for policy and practice. Nicotine Tob Res.
- Behera D, Goswami U, Khastgir U, Kumar S (2003) Craving by imagery cue reactivity in opiate dependence following detoxification. Indian J Psychiatry 45: 178-181.
- Bunce SC, Harris JD, Bixler EO, Taylor M, Muelly E, et al. (2015) Possible evidence for re-regulation of HPA axis and brain reward systems over time in treatment in prescription opioid-dependent patients. J Addict Med 9: 53-60.
- 7. McHugh RK, Park S, Weiss RD (2014) Cueinduced craving in dependence upon prescription opioids and heroin. Am J Addict 23: 453-458.
- Garland EL, Froeliger B, Zeidan F, Partin K, Howard MO (2013) The downward spiral of chronic pain, prescription opioid misuse, and addiction: Cognitive, affective, and neuropsychopharmacologic pathways. Neurosci Biobehav Rev 37: 2597-2607.
- 9. Garland EL, Froeliger B, Howard MO (2014) Effects of mindfulnessoriented recovery enhancement on reward responsiveness and opioid cuereactivity. Psychopharmacology 231: 3229-3238.

- McDonough BE, Warren CA (2001) Effects of 12-h tobacco deprivation on event-related potentials elicited by visual smoking cues. Psychopharmacology 154: 282-291.
- 11. Tiffany ST, Conklin CA (2000) A cognitive processing model of alcohol craving and compulsive alcohol use. Addiction 95: 145-153.
- 12. Field M, Cox WM (2008) Attentional bias in addictive behaviors: A review of its development, causes, and consequences. Drug Alcohol Depend 97: 1-20.
- 13. Upadhyay J, Maleki N, Potter J, Elman I, Rudrauf D, et al. (2010) Alterations in brain structure and functional connectivity in prescription opioid-dependent patients. Brain: A J Neurol 133: 2098-2114.
- Biswal BB, Yetkin FZ, Haughton VM, Hyde JS (1995) Functional connectivity in the motor cortex of resting human brain using echo-planar MRI. Magn Reson Med 34: 537-541.
- Fox MD, Raichle ME (2007) Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging. Nat Rev Neurosci 8: 700-711.
- Bressler SL, Menon V (2010) Large scale brain networks in cognition: emerging methods and principles. Trends Cogn Sci 14: 233-290.
- 17. Yuan R, Di X, Taylor PA, Gohel S, Tsai YH, et al. (2015) Functional topography of the thalamocortical system in human. Brain Struct Funct 221: 1971-1984.
- Vossel S, Geng JJ, Fink GR (2014) Dorsal and ventral attention systems: Distinct neural circuits but collaborative roles. The Neuroscientist 20: 150-159.
- 19. Jasinska AJ, Stein EA, Kaiser J, Naumer MJ, Yalachkov Y (2014) Factors modulating neural reactivity to drug cues in addiction: A survey of human neuroimaging studies. Neurosci Biobehav Rev 38: 1-16.
- 20. Ray S, Haney M, Hanson C, Biswal B, Hanson SJ (2015) Modeling causal relationship between brain regions within the drug-cue processing network in chronic cocaine smokers. Neuropsychopharmacology 40: 2960-2968.